Business Insider
My Markets Watchlist
Markets Stocks

Merck KGaA Stock , MKGAF

114.70 EUR -1.20 -1.04%
03:59:54 PM EDT 6/13/2025 STU
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


Merck Stock Snapshot

57.63 B
Market Cap in USD
129.24 M
Number of Shares
434.78 M
Total Number of Shares
2.20
Dividend in EUR
1.57
Dividend Yield
21.90
P/E Ratio
100.00
Free Float in %
6.39
EPS in EUR
68.80
Book Value per Share in EUR
10.55
Cash Flow per Share in EUR

Historical Prices for Merck

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Merck Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price

Merck Estimates* in EUR

  2025 2026 2027 2028 2029
Revenue 21,616 22,503 23,281 24,569 25,875
Dividend 2.29 2.48 2.53 2.50 2.63
Dividend Yield (in %) 2.00 % 2.16 % 2.20 % 2.18 % 2.29 %
EPS 8.70 9.51 10.14 11.01 11.79
P/E Ratio 13.19 12.08 11.32 10.43 9.74
EBIT 4,346 4,741 4,987 5,133 5,596
EBITDA 6,110 6,537 6,870 7,338 7,840
Net Profit 3,793 4,077 4,365 4,714 -
Net Profit Adjusted 3,793 4,077 4,365 4,714 5,081
Pre-Tax Profit 4,095 4,514 4,849 4,973 5,301
Pre-Tax Profit Reported 3,883 4,297 4,602 4,973 5,301
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 7.01 7.77 8.32 8.90 9.49
Gross Income 12,831 13,511 14,069 15,204 16,271
Cash Flow from Investing -3,247 -2,093 -2,228 -2,516 -2,848
Cash Flow from Operations 5,018 5,172 5,425 6,029 6,657
Cash Flow from Financing -1,076 -1,610 -1,586 -1,753 -1,995
Cash Flow per Share 11.71 12.14 12.71 13.38 14.50
Free Cash Flow 2,508 2,948 3,034 2,826 2,765
Free Cash Flow per Share 4.28 5.52 5.80 4.70 5.53
Book Value per Share 73.84 79.29 85.24 91.57 98.95
Net Debt 6,544 4,579 2,254 1,190 -22
Research & Development Exp. 2,353 2,467 2,518 2,680 2,775
Capital Expenditure 2,167 2,048 2,093 2,236 2,259
Selling, General & Admin. Exp. 6,243 6,376 6,528 6,960 7,228
Shareholder’s Equity 32,100 34,414 36,933 39,381 42,503
Total Assets 53,675 55,490 57,627 60,977 64,377
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 5 5 17 17
Average Estimate - 2.172 EUR 2.217 EUR 8.760 EUR 9.542 EUR
Year Ago - 1.396 EUR 1.861 EUR 6.387 EUR -
Publish Date - - - - -
Revenue Estimates
No. of Analysts - 4 4 16 16
Average Estimate - 5,357 EUR 5,432 EUR 21,643 EUR 22,524 EUR
Year Ago - 5,352 EUR 5,266 EUR 21,156 EUR -
Publish Date - - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. EUR

2024 2023 2022 2021 2020 2019 2018
Sales 21,156.00 20,993.00 22,232.00 19,687.00 17,534.00 16,152.00 14,836.00
Change of sales in % 0.78 -5.57 12.93 12.28 8.56 8.87 -3.20
Gross profit on sales 11,945.00 11,669.00 12,839.00 11,595.00 9,983.00 9,154.40 8,408.30
Gross profit on sales change in % 2.37 -9.11 10.73 16.15 9.05 8.87 -5.69
Operating income 4,362.00 4,043.00 5,067.00 4,282.00 3,150.00 2,000.00 1,753.00
Operating income change in % 7.89 -20.21 18.33 35.94 57.50 14.09 -20.71
Income before tax 3,536.00 3,484.00 4,287.00 3,924.00 2,630.00 1,735.00 1,461.00
Income before tax change in % 1.49 -18.73 9.25 49.20 51.59 18.75 -34.31
Income after tax 2,777.00 2,824.00 3,325.00 3,055.00 1,987.00 1,292.00 1,093.00
Income after tax change in % -1.66 -15.07 8.84 53.75 53.79 18.21 -57.96

Balance Sheet in Mio. EUR

2024 2023 2022 2021 2020 2019 2018
Total liabilities 22,107.00 22,367.00 23,041.00 24,424.00 25,187.00 26,288.00 20,170.00
Long-term liabilities per share 24.87 31.44 31.11 32.18 36.70 33.23 26.80
Equity 29,987.00 26,755.00 26,005.00 21,416.00 17,017.00 17,913.00 17,233.00
Equity change in % 12.11 2.90 21.51 25.92 -5.14 3.87 22.83
Balance sheet total 52,094.00 49,122.00 49,046.00 45,840.00 42,204.00 44,201.00 37,403.00
Balance sheet total change in % 6.05 0.15 6.99 8.62 -4.52 18.18 3.72

Key Data in EUR

2024 2023 2022 2021 2020 2019 2018
Sales per share 48.66 48.28 51.13 45.28 40.33 37.15 34.12
P/E ratio (year end quote, basic EPS) 21.90 22.19 23.65 32.31 30.71 34.70 34.62
P/E ratio (year end quote, diluted EPS) 21.90 22.19 23.65 32.31 30.71 34.70 34.62
Dividend yield in % 1.57 1.53 1.22 0.81 1.00 1.23 1.39
Equity ratio in % 57.56 54.47 53.02 46.72 40.32 40.53 46.07
Debt ratio in % 42.44 45.53 46.98 53.28 59.68 59.47 53.93

Merck Dividend Calendar

Date Name Dividend *yield Currency
2024 Merck KGaA 2.20 1.57 EUR
2023 Merck KGaA 2.20 1.53 EUR
2022 Merck KGaA 2.20 1.22 EUR
2021 Merck KGaA 1.85 0.81 EUR
2020 Merck KGaA 1.40 1.00 EUR
2019 Merck KGaA 1.30 1.23 EUR
2018 Merck KGaA 1.25 1.39 EUR
2017 Merck KGaA 1.25 1.39 EUR
2016 Merck KGaA 1.20 1.21 EUR
2015 Merck KGaA 1.05 1.17 EUR
2014 Merck KGaA 1.00 1.28 EUR
2013 Merck KGaA 0.95 1.46 EUR
2012 Merck KGaA 0.85 1.70 EUR
2011 Merck KGaA 0.75 1.95 EUR
2010 Merck KGaA 0.63 2.09 EUR
2009 Merck KGaA 0.50 1.53 EUR
2008 Merck KGaA 0.75 2.33 EUR
2007 Merck KGaA 1.60 3.62 EUR
2006 Merck KGaA 0.53 1.34 EUR
2005 Merck KGaA 0.43 1.22 EUR
2004 Merck KGaA 0.40 1.58 EUR
2003 Merck KGaA 0.40 2.42 EUR
2002 Merck KGaA 0.50 3.94 EUR
2001 Merck KGaA 0.48 2.29 EUR
2000 Merck KGaA 0.45 1.91 EUR
1999 Merck KGaA 0.43 2.74 EUR
*Yield of the Respective Date

Merck Calendar

Event Estimate Info Date

Merck Past Events

Event Actual EPS Info Date

Merck Profile

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany. .

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Merck Management

Name Job
Belén Garijo López Chairman-Executive Board & CEO
Michael Kleinemeier Chairman-Supervisory Board
Kai Beckmann Chief Executive Officer-Electronics
Danny Bar-Zohar Chief Executive Officer-Healthcare
Matthias J. Heinzel Chief Executive Officer-Life Science Division
Helene von Roeder Chief Financial Officer & Member-Executive Board
Andrew Paterson Chief Marketing Officer
Khadija Ben Hammada Chief People Officer
Laura Matz Chief Science & Technology Officer
Joern-Peter Halle Chief Strategy Officer
Karen N. Madden Head-Canada Life Science business
Hong Chow Head-China & International Healthcare
Albert Langenstein Head-Controlling, Performance Materials
Katherine M. Dei Cas Head-Delivery Systems & Services
Martin Hostalek Head-Group Function Environment, Health & Safety
Constantin Fest Head-Investor Relations
Jeff White Head-Surface Solutions
Renate Koehler Member-Supervisory Board
Peter Emanuel Merck Member-Supervisory Board
Christian Raabe Member-Supervisory Board
Daniel Thelen Member-Supervisory Board
Dietmar Oeter Member-Supervisory Board
Barbara Lambert Member-Supervisory Board
Gabriele Eismann Member-Supervisory Board
Anne Lange Member-Supervisory Board
Jürgen Glaser Member-Supervisory Board
Simon Thelen Member-Supervisory Board
Alexander Putz Member-Supervisory Board
Birgit Biermann Member-Supervisory Board
Helga Rübsamen-Schaeff Member-Supervisory Board
Rüdiger Weseloh Senior Director-Business Development
Sascha Held Vice Chairman-Supervisory Board